BRPI0111222B8 - derivados fosfonados de glicopeptídeo. - Google Patents

derivados fosfonados de glicopeptídeo.

Info

Publication number
BRPI0111222B8
BRPI0111222B8 BRPI0111222A BR0111222A BRPI0111222B8 BR PI0111222 B8 BRPI0111222 B8 BR PI0111222B8 BR PI0111222 A BRPI0111222 A BR PI0111222A BR 0111222 A BR0111222 A BR 0111222A BR PI0111222 B8 BRPI0111222 B8 BR PI0111222B8
Authority
BR
Brazil
Prior art keywords
glycopeptide
derivatives
phosphonate derivatives
disclosed
phosphonate
Prior art date
Application number
BRPI0111222A
Other languages
English (en)
Portuguese (pt)
Other versions
BRPI0111222B1 (pt
BR0111222A (pt
Inventor
S Linsell Martin
R Leadbeetter Michael
Original Assignee
Cumberland Pharmaceuticals Inc
Theravance Biopharma Antibiotics Ip Llc
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cumberland Pharmaceuticals Inc, Theravance Biopharma Antibiotics Ip Llc, Theravance Inc filed Critical Cumberland Pharmaceuticals Inc
Publication of BR0111222A publication Critical patent/BR0111222A/pt
Publication of BRPI0111222B1 publication Critical patent/BRPI0111222B1/pt
Publication of BRPI0111222B8 publication Critical patent/BRPI0111222B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
BRPI0111222A 2000-06-22 2001-05-01 derivados fosfonados de glicopeptídeo. BRPI0111222B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21341000P 2000-06-22 2000-06-22
PCT/US2001/013998 WO2001098328A2 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Publications (3)

Publication Number Publication Date
BR0111222A BR0111222A (pt) 2003-04-01
BRPI0111222B1 BRPI0111222B1 (pt) 2015-03-17
BRPI0111222B8 true BRPI0111222B8 (pt) 2021-05-25

Family

ID=22795013

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0111222A BRPI0111222B8 (pt) 2000-06-22 2001-05-01 derivados fosfonados de glicopeptídeo.

Country Status (36)

Country Link
US (10) US6635618B2 (US07008923-20060307-C00010.png)
EP (1) EP1292612B1 (US07008923-20060307-C00010.png)
JP (2) JP3900491B2 (US07008923-20060307-C00010.png)
KR (1) KR100768488B1 (US07008923-20060307-C00010.png)
CN (1) CN100469788C (US07008923-20060307-C00010.png)
AR (1) AR035333A1 (US07008923-20060307-C00010.png)
AT (1) ATE337334T1 (US07008923-20060307-C00010.png)
AU (2) AU6110701A (US07008923-20060307-C00010.png)
BR (1) BRPI0111222B8 (US07008923-20060307-C00010.png)
CA (2) CA2713965A1 (US07008923-20060307-C00010.png)
CY (2) CY1105194T1 (US07008923-20060307-C00010.png)
CZ (1) CZ303672B6 (US07008923-20060307-C00010.png)
DE (2) DE60122516T2 (US07008923-20060307-C00010.png)
DK (1) DK1292612T3 (US07008923-20060307-C00010.png)
EA (1) EA005953B1 (US07008923-20060307-C00010.png)
EG (1) EG26726A (US07008923-20060307-C00010.png)
ES (1) ES2271012T3 (US07008923-20060307-C00010.png)
HK (1) HK1052191B (US07008923-20060307-C00010.png)
HR (1) HRP20020888B1 (US07008923-20060307-C00010.png)
HU (2) HU229370B1 (US07008923-20060307-C00010.png)
IL (1) IL152408A (US07008923-20060307-C00010.png)
IS (1) IS2303B (US07008923-20060307-C00010.png)
LU (1) LU91908I2 (US07008923-20060307-C00010.png)
MX (1) MXPA02012745A (US07008923-20060307-C00010.png)
MY (1) MY127081A (US07008923-20060307-C00010.png)
NO (2) NO330360B1 (US07008923-20060307-C00010.png)
NZ (1) NZ522279A (US07008923-20060307-C00010.png)
PL (1) PL207101B1 (US07008923-20060307-C00010.png)
PT (1) PT1292612E (US07008923-20060307-C00010.png)
RS (1) RS50499B (US07008923-20060307-C00010.png)
SI (1) SI1292612T1 (US07008923-20060307-C00010.png)
SK (1) SK287470B6 (US07008923-20060307-C00010.png)
TW (1) TWI305209B (US07008923-20060307-C00010.png)
UA (1) UA75083C2 (US07008923-20060307-C00010.png)
WO (1) WO2001098328A2 (US07008923-20060307-C00010.png)
ZA (1) ZA200209419B (US07008923-20060307-C00010.png)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2336445C (en) * 1998-12-23 2011-07-19 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
SI1278549T1 (sl) 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
US6878686B2 (en) 2002-05-24 2005-04-12 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US6951963B2 (en) 2002-06-17 2005-10-04 Theravance, Inc. Process for preparing N-protected β-amino aldehyde compounds
WO2004110473A1 (en) * 2003-05-27 2004-12-23 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
JP4664912B2 (ja) * 2003-07-22 2011-04-06 セラヴァンス， インコーポレーテッド グリコペプチド抗菌剤と組み合わせたエキノカンジン抗真菌剤の使用
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
WO2007082206A2 (en) * 2006-01-10 2007-07-19 Yu Ruey J N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
JP2008112847A (ja) * 2006-10-30 2008-05-15 Shin Etsu Chem Co Ltd 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池
WO2008077241A1 (en) 2006-12-22 2008-07-03 Targanta Therapeutics, Inc. Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
US20090069219A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched telavancin
US8741966B2 (en) 2007-11-09 2014-06-03 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
AU2008343502A1 (en) * 2007-12-26 2009-07-09 Biomarin Pharmaceutical Inc. Novel semi-synthetic glycopeptides as antibacterial agents
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
WO2010048340A2 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
US9682061B2 (en) 2009-04-28 2017-06-20 The Medicines Company Methods of treating bacterial infections using oritavancin
JP5843755B2 (ja) 2009-05-08 2016-01-13 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸
WO2011005959A1 (en) 2009-07-09 2011-01-13 Plus Chemicals Sa Process for the preparation of n-protected-decylaminoethanal
SG190114A1 (en) 2010-11-05 2013-07-31 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2013034676A1 (en) 2011-09-09 2013-03-14 Sandoz Ag Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an n-protected imine-derivative of telavancin
EP2753638A1 (en) 2011-09-09 2014-07-16 Sandoz AG Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof
JP5724937B2 (ja) * 2012-04-23 2015-05-27 ニプロ株式会社 腎臓集積性を示すペプチド、製剤
CN103897040B (zh) * 2012-12-27 2018-05-22 浙江医药股份有限公司新昌制药厂 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途
MX2015011074A (es) 2013-02-28 2016-03-09 Pronova Biopharma Norge As Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
TN2017000358A1 (en) 2015-02-23 2019-01-16 Theravance Biopharma Antibiotics Ip Llc Doses and methods of administering telavancin
JP6784696B2 (ja) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
CN106188243B (zh) * 2015-05-05 2020-06-26 博瑞生物医药（苏州）股份有限公司 一种奥利万星的制备方法
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
BR112018072948A2 (pt) 2016-05-09 2019-02-19 Xellia Pharmaceuticals Aps composição farmacêutica líquida, e, método para a estabilização de um antibiótico glicopeptídeo em uma solução farmacêutica líquida.
JP7210476B2 (ja) 2017-05-22 2023-01-23 インスメッド インコーポレイテッド リポ‐グリコペプチド可切断性誘導体及びその使用
CN107629116B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107629115B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107987131B (zh) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的化合物、其制备方法和应用
KR20200096791A (ko) 2017-12-06 2020-08-13 바스프 에이에스 비알콜성 지방간염 치료용 지방산 유도체
CN108409837B (zh) 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用
JP2022507357A (ja) * 2018-11-21 2022-01-18 インスメッド インコーポレイテッド リポグリコペプチドクリーバブル誘導体およびそれらの使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872A (en) * 1849-11-13 Means of changing the combination in bevolving tumbler-locks
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ZA909847B (en) * 1989-12-13 1992-08-26 Lilly Co Eli Glycopeptide derivatives
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JPH08503951A (ja) 1992-12-02 1996-04-30 インサイト・ビジョン・インコーポレイテッド シクロデキストリンとポリマーを用いた薬剤供給系
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
UA43323C2 (uk) 1994-01-28 2001-12-17 Елі Ліллі Енд Компані Антибіотичні похідні глікопептидів, спосіб отримання та фармацевтична композиція
US5614615A (en) 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
WO1999017793A1 (fr) * 1997-10-03 1999-04-15 Fujisawa Pharmaceutical Co., Ltd. Chlorhydrates de vancomycines antibiotiques et leur procede de production
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
NZ509165A (en) * 1998-07-14 2003-08-29 Univ Princeton Glycopeptide antobiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
CA2336445C (en) * 1998-12-23 2011-07-19 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
CA2370782A1 (en) 1999-04-02 2000-10-12 The Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
JP2000302687A (ja) 1999-04-22 2000-10-31 Sagami Chem Res Center 抗菌性オリゴマー及び抗菌剤
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
SI1278549T1 (sl) 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
EP2263654B1 (en) 2000-06-21 2012-10-10 Cubist Pharmaceuticals, Inc. Compositions for improving the oral absorption of antimicrobial agents
WO2001098326A2 (en) 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives

Also Published As

Publication number Publication date
US20060063706A1 (en) 2006-03-23
HUP0301320A3 (en) 2007-05-29
JP2004501161A (ja) 2004-01-15
CA2411590A1 (en) 2001-12-27
EA200300050A1 (ru) 2003-04-24
NO20025954D0 (no) 2002-12-11
ES2271012T3 (es) 2007-04-16
US7351691B2 (en) 2008-04-01
US8859506B2 (en) 2014-10-14
CY1105194T1 (el) 2010-03-03
US6887976B2 (en) 2005-05-03
JP3900491B2 (ja) 2007-04-04
KR20030032970A (ko) 2003-04-26
HU229370B1 (hu) 2013-11-28
PT1292612E (pt) 2006-12-29
HRP20020888B1 (en) 2007-12-31
RS50499B (sr) 2010-03-02
US20100160211A1 (en) 2010-06-24
SK287470B6 (sk) 2010-10-07
SK18522002A3 (sk) 2003-06-03
CZ20023942A3 (cs) 2003-03-12
NZ522279A (en) 2004-07-30
CY2012006I2 (el) 2016-06-22
CY2012006I1 (el) 2016-06-22
NO330360B1 (no) 2011-04-04
NO2011025I2 (US07008923-20060307-C00010.png) 2011-11-18
HUS1400024I1 (hu) 2017-03-28
TWI305209B (en) 2009-01-11
EG26726A (en) 2014-06-18
DE60122516T2 (de) 2007-01-04
CA2713965A1 (en) 2001-12-27
BRPI0111222B1 (pt) 2015-03-17
WO2001098328A3 (en) 2002-04-11
CA2411590C (en) 2010-10-19
IS6600A (is) 2002-10-29
SI1292612T1 (sl) 2006-12-31
US20020022590A1 (en) 2002-02-21
AU6110701A (en) 2002-01-02
CN1437611A (zh) 2003-08-20
EP1292612A2 (en) 2003-03-19
NO2011025I1 (no) 2011-11-18
UA75083C2 (uk) 2006-03-15
HUP0301320A2 (hu) 2003-08-28
US6635618B2 (en) 2003-10-21
US8541375B2 (en) 2013-09-24
CZ303672B6 (cs) 2013-02-20
US8101575B2 (en) 2012-01-24
PL207101B1 (pl) 2010-11-30
US20040063916A1 (en) 2004-04-01
MY127081A (en) 2006-11-30
MXPA02012745A (es) 2004-04-05
US20120283195A1 (en) 2012-11-08
IL152408A (en) 2009-05-04
DK1292612T3 (da) 2007-01-02
US20140024604A1 (en) 2014-01-23
HK1052191B (zh) 2007-01-26
PL359419A1 (en) 2004-08-23
CN100469788C (zh) 2009-03-18
US20070049519A1 (en) 2007-03-01
ZA200209419B (en) 2004-02-19
IL152408A0 (en) 2003-05-29
EP1292612B1 (en) 2006-08-23
JP2007045842A (ja) 2007-02-22
DE122011100062I1 (de) 2012-03-15
DE60122516D1 (de) 2006-10-05
US20080312407A1 (en) 2008-12-18
US7008923B2 (en) 2006-03-07
US20050164916A1 (en) 2005-07-28
HK1052191A1 (en) 2003-09-05
LU91908I2 (fr) 2012-01-30
ATE337334T1 (de) 2006-09-15
YU96902A (sh) 2006-01-16
EA005953B1 (ru) 2005-08-25
IS2303B (is) 2007-10-15
US7208471B2 (en) 2007-04-24
HRP20020888A2 (en) 2005-02-28
US6872701B2 (en) 2005-03-29
WO2001098328A2 (en) 2001-12-27
AU2001261107B2 (en) 2006-07-20
BR0111222A (pt) 2003-04-01
US20030207797A1 (en) 2003-11-06
AR035333A1 (es) 2004-05-12
NO20025954L (no) 2002-12-11
US7700550B2 (en) 2010-04-20
KR100768488B1 (ko) 2007-10-18

Similar Documents

Publication Publication Date Title
BRPI0111222B8 (pt) derivados fosfonados de glicopeptídeo.
BR9914221B1 (pt) Derivados de glicopeptídeos e composições farmacêuticas contendo os mesmos
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
BR0112030A (pt) Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
DE69608916D1 (de) Verbindungen und ihre zusammensetzungen mit entzündungshemmenden und anti-thrombotischen wirkungen
ATE231872T1 (de) Thiazolopyrimidinderivate
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
ECSP034442A (es) Mezclas de polisacaridos derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienen
CY1105482T1 (el) Χρηση της αζιθρομυκινης στην τοπικη αγωγη οφθαλμικων μολυνσεων
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
SE9801494D0 (sv) Novel use
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
EP1073447A4 (en) N1-MODIFIED GLYCOPEPTIDES
ATE305517T1 (de) Neurotrypsin
BR9902347A (pt) Azabiciclos como inibidores de rotomase
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
TR200103169T2 (tr) 1,5-Benzodiazepin türevleri
PT1140932E (pt) Derivados de 1,8-benzonaftiridina
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents
SV2002000210A (es) Profarmacos de higromicina a ref. pc10548ajnm/bb

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/03/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/05/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/05/2021